Trials / Completed
CompletedNCT00645320
A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study
An Open Label, Extension Study To Assess The Efficacy And Tolerability Of Oral Ziprasidone In Patients Successfully Completing A Previous Study With Ziprasidone
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and tolerability of ziprasidone in patients who successfully completed a study of ziprasidone treatment of psychosis (Protocol A1281074).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ziprasidone | Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion. |
Timeline
- Start date
- 2003-08-01
- Completion
- 2004-08-01
- First posted
- 2008-03-27
- Last updated
- 2021-02-21
Locations
8 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT00645320. Inclusion in this directory is not an endorsement.